Content about Neurology

NEW YORK — CVS/pharmacy has decided to stock Tylenol pain reliever in only half of its stores, according to a Reuters report published Monday. 

According to the report, CVS will stock Tylenol in each market, but not in each store as CVS seeks to plug any out-of-stock holes left behind by the initial recall of Tylenol three years ago and the brand's slow trek back to shelf. 

PHILADELPHIA — The Food and Drug Administration has granted regulatory approval for a generic drug to treat tension headaches.

Lannett announced the approval of butalbital, acetaminophen and caffeine tablets in the 50-mg/325-mg/40-mg strength. the drug is a generic version of Watson Pharmaceuticals' Fioricet.

Branded and generic versions of the drug had sales of $30 million during the 12-month period ended in July, including $15 million for branded Fioricet. Lannett plans to start shipping its version next month, the company said.

GREENSBORO, N.C. — Merz announced it has acquired a medication designed to treat a condition associated with such neurologic conditions as cerebral palsy.

NEW YORK — A drug made by Pfizer for treating pain disorders doesn't affect men's reproductive functions, according to a new post-approval clinical study.

The drug maker announced Monday the results of study A0081104 of Lyrica (pregabalin), which compared the drug with placebo in healthy males to assess its effects on sperm production. The phase-4 study was required by the Food and Drug Administration.

MORRISTOWN, N.J. — The Food and Drug Administration has approved a generic drug for attention deficit hyperactivity disorder made by Actavis, the drug maker said Monday.

Actavis, whose parent company was recently acquired by Watson Pharmaceuticals, announced the approval of dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules, also known as mixed-amphetamine salts ER capsules.

NEW YORK — The Food and Drug Administration has approved a drug made by GlaxoSmithKline and XenoPort for treating pain associated with shingles.

The drug makers announced Thursday the approval of Horizant (gabapentin enacarbil) extended-release tablets for managing post-herpetic neuralgia. The drug already had FDA approval for treating restless legs syndrome. The approval entitles XenoPort to a $10 million milestone payment from GSK, according to a collaborative agreement between the two companies.

FRISCO, Texas — Summer Soles on Monday announced the launch of five additions to its collection of Softness of Suede insoles that help women keep their feet feeling dry and comfortable during the summer months.

"In summer, all feet sweat, even if you're wearing thongs, sandals or open toed shoes," Summer Soles founder Shannon McLinden said. "These gorgeous and brightly patterned prints keep feet dry for under $10. What's great about these liners is that they are very thin, easy to use and removable."

HAYWARD, Calif. — Generic drug maker Impax Labs is challenging the patent protection on a drug used to treat postherpetic neuralgia, the company said Thursday.

Impax announced that it had filed a regulatory approval application with the Food and Drug Administration for gabapentin tablets, a generic version of Depomed's Gralise, in the 300-mg and 600-mg strengths.

BENTONVILLE, Ark. — Sam's Club is offering free screenings for brain health at all of its stores that operate pharmacies this month, the retailer said Friday.

The company, which has performed more than 1 million health and wellness screenings at it stores since 2011, said it would offer the screenings on April 14 for members and the public, including a memory test and educational materials on Alzheimer's and dementia provided by the Alzheimer's Foundation of America, as well as body mass index, blood pressure and glucose tests.

AMITYVILLE, N.Y. — The Food and Drug Administration has approved a drug for epilepsy made by Hi-Tech Pharmacal, the drug maker said Wednesday.

Hi-Tech announced the approval of levetiracetam oral solution in the 100 mg-per-milliliter strength. The drug is a generic version of UCB Pharma's Keppra oral solution and is used to treat partial onset seizures in people ages 16 years and older.

Various versions of the drug had sales of $62 million in 2011, according to IMS Health. Hi-Tech said it plans to launch the drug in May.

PITTSBURGH — The Food and Drug Administration has approved a drug for epilepsy made by Mylan, the drug maker said.

The FDA approved Mylan's levetiracetam extended-release tablets in the 500-mg and 750-mg strengths.

The drug is a generic version of UCB's Keppra XR, used to treat partial onset seizures in epilepsy patients ages 16 years and older.

Various versions of the drug had sales of about $162.8 million during the 12-month period ended in September, according to IMS Health.

SAM MATEO, Calif. — A Food and Drug Administration expert panel will review a drug made by NeurogesX as a potential treatment for pain associated with HIV.

NeurogesX said Thursday that the FDA Anesthetic and Analgesic Drug Products Advisory Committee would meet on Feb. 9, 2012, to review the patch drug Qutenza (capsaicin) as a treatment for pain associated with HIV-associated peripheral neuropathy, or HIV-PN.

The drug currently is approved for treating pain associated with postherpetic neuralgia.